

References

I-146

1. Ortega H, Liu M, Pavord I, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *New Engl J Med*. 2014; 371(13):1198-1207.
2. Prazma CM, Wenzel S, Barnes N, et al. Characterisation of an oral corticosteroids (OCS) dependent severe asthma population treated with mepolizumab. *Thorax*. 2014; 69(12):1141-1142.
3. Katz, L, Gleich G, Hartley B, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. *Annals Am Thor Soc*. 2014;11(4):531-536.
4. Chung KF, Wenzel SE, Brozek JL, et al. International European Respiratory Society/American Thoracic Society guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014; 43(2):343-373.
5. Nucala (mepolizumab) [package insert]. GlaxoSmithKline LLC. Philadelphia, PA. 09/2020.
6. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2012;456-463.
7. Bjerner L, Lerner C, Maspero J, et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels. *CHEST*. 2016 Oct;150(4):789-798.
8. Clinical Pharmacology Compendia. 2020. Tampa FL: Gold Standard, Inc. Benralizumab.
9. Clinical Pharmacology Compendia. 2020. Tampa FL: Gold Standard, Inc. Mepolizumab.
10. Clinical Pharmacology Compendia. 2020. Tampa FL: Gold Standard, Inc. Reslizumab.
11. Fasenra (benralizumab) injection, for subcutaneous use [package insert]. AstraZeneca Pharmaceuticals LP. Wilmington, DE. October 2019.
12. Cinqair (Reslizumab) injection [package insert]. Teva Respiratory, LLC. West Chester, PA. 02/2020.
13. Pham T, Damera G, Newbold P, & Ranade K. Reductions in Eosinophil Biomarkers by Benralizumab in Patients with Asthma. *Respiratory Medicine*. 2016;111:21-29.
14. Goldman M, Hirsch I, Zangrilli J G, et al. The Association Between Blood Eosinophil Count and Benralizumab Efficacy for Patients with Severe, Uncontrolled Asthma: Subanalyses of the Phase III SIROCCO and CALIMA Studies. *Curr Med Res Opin*. 2017 September;33(9):1605-1613.
15. FitzGerald J M, Bleecker, E R, Menzies-Gow A, et al. Predictors of Enhanced Response with Benralizumab for Patients with Severe Asthma: Pooled Analysis of the SIROCCO and CALIMA Studies. *Lancet*. 2018;6:51-64.
16. Wechsler M E, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. *New Engl J Med*. 2017 May;376(20):1921-1932.

17. Chung K, Wenzel S, Brozek J, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Euro Resp J*. 2014;43:343-373.
18. Roufosse F, Kahn J, Rothenberg M, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial. *J Allergy and Clinical Immunology*. 2020.